VEGFA and head and neck squamous cell carcinoma: Recent studies on the combination of VEGF-TKIs and immunotherapy indicate that such an approach may be promising; in addition to the clinical benefit of both classes of agents, the lack of additive side effects with ICIs, and the broad applicability given no required biomarker or patient selection, all point to a high potential for a promising strategy in treating SCCHN and potentially other SCCs.